Welcome to this week’s latest edition of Weekend Wonderings. Since I write this before the Big Ten Championship Game, the outcome is still in doubt. However the game turns out, I hope you’ve all recovered, for good or ill, and we move on with our lives. And hopefully, we move on to the NCG. Please take a few minutes, grab a beverage and let’s get into this. Also, the Browns play the Patriots today, so you may need to double up the elixir.
Here’s some interesting news from The James. Due to the generous efforts and donations of Pelotonia volunteers and donors, nine research grants have been awarded.
“These pilot grants, funded by Pelotonia, are so critical to ensure that Ohio State stays at the forefront of speeding the development and delivery of treatments that target the molecules and markers fueling each person’s unique cancer,” says Michael Caligiuri, MD, director of OSUCCC and chief executive officer of the James Cancer Hospital & Solove Research Institute. “These projects represent bold, out-of-the box thinking to develop preventions and treatments that target individual cancers. None of these ideas would have been funded—along with so many other big ideas in cancer research—were it not for the thousands and thousands of Pelotonia riders and donors. Each of rider helps bring us closer to our shared vision of a cancer-free world.”
Welcome to another edition of Weekend Wonderings. Take a minute, grab whatever you drink on a Sunday afternoon and let’s carry on.
Go ahead, I’ll wait.
First, by the end of the month, the James will open a Phase 2 clinical trial to test two drugs for the treatment of triple negative breast cancer – a very aggressive type of cancer with high rates of recurrence.
Triple negative breast cancer, which accounts for 15 to 20 percent of breast cancers, is so hard to treat because it doesn’t have any of the receptors (substances found inside cells that give rise to cancer) that existing drugs are able to fight…
Let’s hope that these trials come up with a solution, because if treatment drugs can’t “find” anything to latch onto, the treatment just becomes that more difficult.
Next, is an article written by Sameek Roychowdhury. MD, PhD about the use of genomics in clinical trials.
Gene sequencing technology called next-generation sequencing will enable oncologists to determine which of 200-plus significant genes are altered in a patient’s cancer and to use this information to guide therapy. Ohio State is among the leaders in the country in promoting and championing this precision oncology strategy.
I’m a believer in the use of genomics as both a diagnostic and a treatment approach . There are many “families” of cancer, such as breast, prostate, lung, etc., and several subsets within each family. This is not a one-size-fits-all disease. I’m very familiar with the subsets where there is no definitive cause; which leads to the disease likely being incurable. This genomics approach may get us over that hurdle. Read More